Silexion Therapeutics Corp(SLXN)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

SLXN Silexion Therapeutics Corp

盘前交易 09-10 07:48:23 EDT

0.3495

+0.0046

+1.33%

盘前0.4014

+0.0519+14.85%

07:48 EDT

最高0.3557	最低0.3350	成交量6.74万
今开0.3452	昨收0.3449	日振幅6.00%
总市值201.17万	流通市值198.25万	总股本575.59万
成交额2.29万	换手率1.19%	流通股本567.23万
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

{"stockData":{"symbol":"SLXN","market":"US","secType":"STK","nameCN":"Silexion Therapeutics Corp","latestPrice":0.3495,"timestamp":1788984000000,"preClose":0.3449,"halted":0,"volume":67399,"hourTrading":{"tag":"盘前","latestPrice":0.4014,"preClose":0.3495,"latestTime":"07:48 EDT","volume":23858830,"amount":10378010.0874895,"timestamp":1789040899147,"change":0.0519,"changeRate":0.148498,"amplitude":0.551073},"delay":0,"changeRate":0.013337199188170465,"floatShares":5672255,"shares":5755900,"eps":-56.4473,"marketStatus":"盘前交易","change":0.0046,"latestTime":"09-10 07:48:23 EDT","open":0.3452,"high":0.3557,"low":0.335,"amount":22873.872620000002,"amplitude":0.060017,"askPrice":0.4195,"askSize":3000,"bidPrice":0.3845,"bidSize":100,"shortable":3,"etf":0,"ttmEps":-56.4473,"tradingStatus":1,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1789047000000},"marketStatusCode":1,"adr":0,"exchange":"NASDAQ","adjPreClose":0.3495,"preHourTrading":{"tag":"盘前","latestPrice":0.4014,"preClose":0.3495,"latestTime":"07:48 EDT","volume":23858830,"amount":10378010.0874895,"timestamp":1789040899147,"change":0.0519,"changeRate":0.148498,"amplitude":0.551073},"postHourTrading":{"tag":"盘后","latestPrice":0.3543,"preClose":0.3495,"latestTime":"19:30 EDT","volume":686,"amount":240.1646,"timestamp":1788996607335,"change":0.0048,"changeRate":0.013734,"amplitude":0.049213},"volumeRatio":0.3794646878873224},"requestUrl":"/m/hq/s/SLXN","defaultTab":"news","newsList":[{"id":"1105446011","title":"Silexion Therapeutics Corp 公布 Sil204 在 KRAS 突变癌细胞中的积极临床前研究结果","url":"https://stock-news.laohu8.com/highlight/detail?id=1105446011","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1105446011?lang=zh_cn&edition=full","pubTime":"2026-08-04 21:16","pubTimestamp":1785849395,"startTime":"0","endTime":"0","summary":"Silexion Therapeutics Corp 宣布，其在针对 KRAS 突变癌细胞的研究中，取得了关于 Sil204 的积极临床前发现。这一成果为后续的研发工作奠定了坚实基础。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SLXN","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1197854807","title":"Silexion Therapeutics Corp：以色列与德国新站点将加入Sil204 2/3期临床试验","url":"https://stock-news.laohu8.com/highlight/detail?id=1197854807","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1197854807?lang=zh_cn&edition=full","pubTime":"2026-07-29 19:06","pubTimestamp":1785323184,"startTime":"0","endTime":"0","summary":"Silexion Therapeutics Corp披露，预计在未来数月内，将有更多来自以色列和德国的研究中心加入其Sil204 2/3期临床试验项目。这一举措旨在进一步扩大试验的地域覆盖范围，并推动候选药物的临床开发进程。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SLXN","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1195302666","title":"Silexion Therapeutics 在特拉维夫苏拉斯基医疗中心成功启动 Sil204 针对局部晚期胰腺癌的 2/3 期临床试验","url":"https://stock-news.laohu8.com/highlight/detail?id=1195302666","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1195302666?lang=zh_cn&edition=full","pubTime":"2026-07-29 19:01","pubTimestamp":1785322910,"startTime":"0","endTime":"0","summary":"Silexion Therapeutics（SLXN）已成功在特拉维夫苏拉斯基医疗中心启动旗下药物 Sil204 的 2/3 期临床试验。该试验聚焦于局部晚期胰腺癌患者，标志着该公司在肿瘤治疗领域迈出关键一步。此次启动不仅验证了前期研究的积累，也为后续临床开发奠定了坚实基础。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SLXN","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1191362943","title":"Silexion Therapeutics Corp 宣布：截至2026年7月29日，已获以色列Sil204试验全部监管批准","url":"https://stock-news.laohu8.com/highlight/detail?id=1191362943","media":"美股速递","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1191362943?lang=zh_cn&edition=full","pubTime":"2026-07-29 19:01","pubTimestamp":1785322907,"startTime":"0","endTime":"0","summary":"Silexion Therapeutics Corp 正式通报，截至2026年7月29日，该公司已成功获得在以色列开展Sil204试验所需的所有监管批准。这一里程碑式的进展，标志着其研发管线向前迈出了关键一步。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SLXN","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1161346049","title":"Maxim集团调整目标价至6美元，反映Silexion Therapeutics 1:10并股","url":"https://stock-news.laohu8.com/highlight/detail?id=1161346049","media":"美股速递","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1161346049?lang=zh_cn&edition=full","pubTime":"2026-06-24 13:41","pubTimestamp":1782279675,"startTime":"0","endTime":"0","summary":"Maxim集团调整了Silexion Therapeutics Corp的目标股价。该机构将目标价从60美元下调至6美元，此举旨在反映公司近期完成的1:10反向股票分割。反向股票分割导致流通股数量减少，每股价格相应调整，因此目标价需进行同步修正以保持可比性。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","SLXN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1134010182","title":"Silexion Therapeutics Corp在德国获无条件试验批准，此前伦理委员会给出积极意见","url":"https://stock-news.laohu8.com/highlight/detail?id=1134010182","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1134010182?lang=zh_cn&edition=full","pubTime":"2026-06-23 20:41","pubTimestamp":1782218479,"startTime":"0","endTime":"0","summary":"Silexion Therapeutics Corp宣布，其在德国的临床试验已获无条件批准。这一决定基于德国伦理委员会此前出具的积极意见。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SLXN","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1158403906","title":"Silexion Therapeutics 公布Sil204针对Kras驱动型胰腺癌免疫疗法的积极初步数据","url":"https://stock-news.laohu8.com/highlight/detail?id=1158403906","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1158403906?lang=zh_cn&edition=full","pubTime":"2026-05-14 21:28","pubTimestamp":1778765302,"startTime":"0","endTime":"0","summary":"Silexion Therapeutics Corp 宣布，其针对Kras驱动型胰腺癌的免疫疗法候选药物Sil204，取得了积极的初步研究结果。这一发现为这一难治性癌症领域的治疗带来了新的希望。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","SLXN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1187044421","title":"Silexion Therapeutics宣布启动Sil204的GMP临床供应生产，并获特拉维夫Sourasky医疗中心批准2/3期试验","url":"https://stock-news.laohu8.com/highlight/detail?id=1187044421","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1187044421?lang=zh_cn&edition=full","pubTime":"2026-05-13 20:02","pubTimestamp":1778673723,"startTime":"0","endTime":"0","summary":"Silexion Therapeutics公司宣布，已与一家领先的全球合同开发与生产组织（CDMO）合作，启动了其候选药物Sil204的GMP临床供应生产。与此同时，公司还获得了来自以色列特拉维夫Sourasky医疗中心对其Sil204药物进行2/3期临床试验的新批准。这两项进展标志着该药物临床开发路径上的重要里程碑，为其后续的临床研究推进提供了关键的物料支持和试验场地保障。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SLXN","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1194280405","title":"Silexion Therapeutics成功向德国BfArM提交Sil204针对KRAS驱动局部晚期胰腺癌的II/III期临床试验申请","url":"https://stock-news.laohu8.com/highlight/detail?id=1194280405","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1194280405?lang=zh_cn&edition=full","pubTime":"2026-04-28 20:48","pubTimestamp":1777380512,"startTime":"0","endTime":"0","summary":"Silexion Therapeutics Corp（简称SLXN）宣布，已顺利完成其核心候选药物Sil204针对KRAS基因驱动型局部晚期胰腺癌的II/III期临床试验申请，并正式提交至德国联邦药品和医疗器械研究所（BfArM）。这一关键进展标志着该创新疗法向临床验证迈出重要一步，为全球胰腺癌患者带来新的治疗希望。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","SLXN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1128273196","title":"Silexion Therapeutics计划本季度末在德国提交2/3期临床试验申请，并拟于2027年初在欧盟提交额外监管申请","url":"https://stock-news.laohu8.com/highlight/detail?id=1128273196","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1128273196?lang=zh_cn&edition=full","pubTime":"2026-03-24 20:39","pubTimestamp":1774355952,"startTime":"0","endTime":"0","summary":"Silexion Therapeutics Corp宣布，计划在本季度末前向德国监管机构提交其2/3期临床试验的申请。此外，公司还预计将在2027年初于欧盟范围内提交额外的监管申请文件。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SLXN","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1158550340","title":"Silexion Therapeutics获以色列卫生部批准 启动Sil204治疗局部晚期胰腺癌的2/3期临床试验","url":"https://stock-news.laohu8.com/highlight/detail?id=1158550340","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1158550340?lang=zh_cn&edition=full","pubTime":"2026-03-24 20:38","pubTimestamp":1774355925,"startTime":"0","endTime":"0","summary":"Silexion Therapeutics Corp已正式获得以色列卫生部批准，将启动其核心候选药物Sil204针对局部晚期胰腺癌的2/3期临床试验。这一关键监管许可标志着该药物临床开发进程中的重要一步，为评估其在治疗这一难治性癌症方面的潜力铺平了道路。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SLXN","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1112627847","title":"Silexion Therapeutics公布2025年第四季度及全年财务业绩并更新业务进展","url":"https://stock-news.laohu8.com/highlight/detail?id=1112627847","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1112627847?lang=zh_cn&edition=full","pubTime":"2026-03-18 05:02","pubTimestamp":1773781344,"startTime":"0","endTime":"0","summary":"Silexion Therapeutics Corp公布了2025年第四季度及全年的财务业绩，并同步更新了公司最新的业务动态。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SLXN","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2511669489","title":"Silexion Therapeutics Corp盘中异动 股价大跌6.69%","url":"https://stock-news.laohu8.com/highlight/detail?id=2511669489","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2511669489?lang=zh_cn&edition=full","pubTime":"2025-02-14 23:23","pubTimestamp":1739546591,"startTime":"0","endTime":"0","summary":"北京时间2025年02月14日23时23分，Silexion Therapeutics Corp股票出现波动，股价大幅下跌6.69%。Silexion Therapeutics Corp股票所在的生物技术行业中，整体跌幅为0.11%。其相关个股中，Moleculin Biotech, Inc.、Psyence Biomedical Ltd C/Wts 25/01/2029、Cns Pharmaceuticals, Inc.涨幅较大，Moleculin Biotech, Inc.、Cns Pharmaceuticals, Inc.、Virpax Pharmaceuticals, Inc.较为活跃，换手率分别为2430.41%、627.61%、476.65%，振幅较大的相关个股有Moleculin Biotech, Inc.、Psyence Biomedical Ltd C/Wts 25/01/2029、Klotho Neurosciences Inc C/Wts 21/06/2029 ，振幅分别为66.93%、54.40%、43.67%。Silexion Therapeutics Corp公司简介：Silexion Therapeutics Corp是一家处于发展阶段的公司，致力于开发胰腺癌治疗方法。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250214232311abcf1263&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250214232311abcf1263&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","LENZ","SLXN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2511529975","title":"Silexion Therapeutics Corp盘中异动 早盘急速下跌5.19%报1.28美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2511529975","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2511529975?lang=zh_cn&edition=full","pubTime":"2025-02-13 22:47","pubTimestamp":1739458051,"startTime":"0","endTime":"0","summary":"北京时间2025年02月13日22时47分，Silexion Therapeutics Corp股票出现异动，股价快速下挫5.19%。截至发稿，该股报1.28美元/股，成交量11.07万股，换手率2.77%，振幅3.70%。Silexion Therapeutics Corp股票所在的生物技术行业中，整体涨幅为0.03%。Silexion Therapeutics Corp公司简介：Silexion Therapeutics Corp是一家处于发展阶段的公司，致力于开发胰腺癌治疗方法。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250213224731a244af6f&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250213224731a244af6f&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LENZ","SLXN","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2510289338","title":"Silexion Therapeutics Corp盘中异动 早盘急速拉升6.87%报1.40美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2510289338","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2510289338?lang=zh_cn&edition=full","pubTime":"2025-02-11 22:31","pubTimestamp":1739284262,"startTime":"0","endTime":"0","summary":"北京时间2025年02月11日22时31分，Silexion Therapeutics Corp股票出现异动，股价快速上涨6.87%。截至发稿，该股报1.40美元/股，成交量84.0262万股，换手率21.03%，振幅0.00%。Silexion Therapeutics Corp股票所在的生物技术行业中，整体跌幅为0.92%。Silexion Therapeutics Corp公司简介：Silexion Therapeutics Corp是一家处于发展阶段的公司，致力于开发胰腺癌治疗方法。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250211223102a241fac2&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250211223102a241fac2&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LENZ","SLXN","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2510864637","title":"Silexion Therapeutics Corp盘中异动 早盘股价大涨5.56%","url":"https://stock-news.laohu8.com/highlight/detail?id=2510864637","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2510864637?lang=zh_cn&edition=full","pubTime":"2025-02-10 23:55","pubTimestamp":1739202912,"startTime":"0","endTime":"0","summary":"北京时间2025年02月10日23时55分，Silexion Therapeutics Corp股票出现异动，股价快速上涨5.56%。Silexion Therapeutics Corp股票所在的生物技术行业中，整体跌幅为0.03%。其相关个股中，60 Degrees Pharmaceuticals Inc C/Wts 12/07/2028 、Biodexa Pharmaceuticals Plc、Neurosense Therapeutics Ltd C/Wts 10/11/2026 涨幅较大，Biodexa Pharmaceuticals Plc、Nls Pharmaceutics Ltd.、Ocean Biomedical, Inc.较为活跃，换手率分别为2678.06%、1538.49%、1022.06%，振幅较大的相关个股有Abpro Holdings Inc C/Wts 12/11/2029 、Ocean Biomedical, Inc.、Biodexa Pharmaceuticals Plc，振幅分别为87.80%、76.30%、66.09%。Silexion Therapeutics Corp公司简介：Silexion Therapeutics Corp是一家处于发展阶段的公司，致力于开发胰腺癌治疗方法。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250210235512abc9b70b&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250210235512abc9b70b&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["SLXN","BK4139","LENZ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2509974474","title":"Silexion Therapeutics Corp盘中异动 股价大跌6.25%报1.35美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2509974474","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2509974474?lang=zh_cn&edition=full","pubTime":"2025-02-07 22:37","pubTimestamp":1738939048,"startTime":"0","endTime":"0","summary":"北京时间2025年02月07日22时37分，Silexion Therapeutics Corp股票出现波动，股价快速下挫6.25%。截至发稿，该股报1.35美元/股，成交量21.6598万股，换手率5.42%，振幅4.86%。Silexion Therapeutics Corp股票所在的生物技术行业中，整体涨幅为0.02%。Silexion Therapeutics Corp公司简介：Silexion Therapeutics Corp是一家处于发展阶段的公司，致力于开发胰腺癌治疗方法。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250207223728987daea2&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250207223728987daea2&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LENZ","SLXN","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2509282483","title":"Silexion Therapeutics Corp盘中异动涨6.00% 振幅达10.00%","url":"https://stock-news.laohu8.com/highlight/detail?id=2509282483","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2509282483?lang=zh_cn&edition=full","pubTime":"2025-02-05 22:36","pubTimestamp":1738766204,"startTime":"0","endTime":"0","summary":"北京时间2025年02月05日22时36分，Silexion Therapeutics Corp股票出现波动，股价快速上涨6.00%。截至发稿，该股报1.33美元/股，成交量43.6581万股，换手率10.93%，振幅10.00%。Silexion Therapeutics Corp股票所在的生物技术行业中，整体涨幅为0.78%。Silexion Therapeutics Corp公司简介：Silexion Therapeutics Corp是一家处于发展阶段的公司，致力于开发胰腺癌治疗方法。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250205223644987b7cbc&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250205223644987b7cbc&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LENZ","BK4139","SLXN"],"isVideo":false,"video":null,"gpt_icon":1},{"id":"2508845726","title":"Silexion Therapeutics Corp盘中异动 急速跳水5.10%报1.49美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2508845726","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2508845726?lang=zh_cn&edition=full","pubTime":"2025-02-04 22:31","pubTimestamp":1738679480,"startTime":"0","endTime":"0","summary":"北京时间2025年02月04日22时31分，Silexion Therapeutics Corp股票出现波动，股价快速下跌5.10%。Silexion Therapeutics Corp股票所在的生物技术行业中，整体跌幅为0.58%。其相关个股中，Azitra Inc、Evaxion Biotech As、Achilles Therapeutics Plc Ads Each Repr 1 Share Spon涨幅较大，Azitra Inc、Evaxion Biotech As、Enveric Biosciences, Inc.较为活跃，换手率分别为836.24%、675.65%、185.77%，振幅较大的相关个股有Coeptis Therapeutics Holdings Inc C/Wts 28/10/2027 、Omega Therapeutics, Inc.、Azitra Inc，振幅分别为19.74%、18.97%、14.22%。Silexion Therapeutics Corp公司简介：Silexion Therapeutics Corp是一家处于发展阶段的公司，致力于开发胰腺癌治疗方法。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250204223121a239289f&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250204223121a239289f&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["SLXN","LENZ","BK4139"],"isVideo":false,"video":null,"gpt_icon":1},{"id":"2508141854","title":"Silexion Therapeutics Corp盘中异动 大幅跳水14.21%报1.63美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2508141854","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2508141854?lang=zh_cn&edition=full","pubTime":"2025-02-03 22:31","pubTimestamp":1738593074,"startTime":"0","endTime":"0","summary":"北京时间2025年02月03日22时31分，Silexion Therapeutics Corp股票出现波动，股价急速下挫14.21%。Silexion Therapeutics Corp股票所在的生物技术行业中，整体跌幅为0.29%。其相关个股中，Hcw Biologics Inc.、Gh Research Plc、Briacell Therapeutics Corp.涨幅较大，Hcw Biologics Inc.、Briacell Therapeutics Corp.、Cyclerion Therapeutics, Inc.较为活跃，换手率分别为312.19%、197.59%、126.11%，振幅较大的相关个股有Jupiter Neurosciences, Inc.、Lipocine Inc.、Biocardia, Inc.，振幅分别为4.85%、4.40%、4.05%。Silexion Therapeutics Corp公司简介：Silexion Therapeutics Corp是一家处于发展阶段的公司，致力于开发胰腺癌治疗方法。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250203223114abc1065f&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250203223114abc1065f&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LENZ","SLXN","BK4139"],"isVideo":false,"video":null,"gpt_icon":1}],"profile":{"websiteUrl":"http://www.silexion.com","stockEarnings":[{"period":"1week","weight":-0.0048},{"period":"1month","weight":-0.767},{"period":"3month","weight":-0.8869},{"period":"6month","weight":-0.9782},{"period":"1year","weight":-0.9931},{"period":"ytd","weight":-0.9818}],"compareEarnings":[{"period":"1week","weight":-0.0036},{"period":"1month","weight":-0.0138},{"period":"3month","weight":0.0334},{"period":"6month","weight":0.1512},{"period":"1year","weight":0.1723},{"period":"ytd","weight":0.118}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"Silexion Therapeutics Corp是一家开曼群岛豁免公司。该公司是一家临床阶段、专注于肿瘤学的生物技术公司，致力于开发针对KRAS突变驱动的癌症的专有疗法。其主要候选药物SIL204是一种旨在抑制突变KRAS蛋白产生的第二代小干扰RNA，最初针对局部晚期胰腺癌。","yearOnYearQuotes":[{"month":1,"riseRate":0.4,"avgChangeRate":-0.016335},{"month":2,"riseRate":0.6,"avgChangeRate":-0.095221},{"month":3,"riseRate":0.8,"avgChangeRate":-0.040641},{"month":4,"riseRate":0.6,"avgChangeRate":-0.119987},{"month":5,"riseRate":0.333333,"avgChangeRate":-0.024382},{"month":6,"riseRate":0.333333,"avgChangeRate":-0.109699},{"month":7,"riseRate":0.833333,"avgChangeRate":0.002605},{"month":8,"riseRate":0.333333,"avgChangeRate":-0.365349},{"month":9,"riseRate":0.5,"avgChangeRate":-0.201505},{"month":10,"riseRate":0.4,"avgChangeRate":-0.091257},{"month":11,"riseRate":0.4,"avgChangeRate":-0.018649},{"month":12,"riseRate":0.2,"avgChangeRate":-0.12005}],"exchange":"NASDAQ","name":"Silexion Therapeutics Corp","nameEN":"Silexion Therapeutics Corp"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Silexion Therapeutics Corp(SLXN)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供Silexion Therapeutics Corp(SLXN)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"Silexion Therapeutics Corp,SLXN,Silexion Therapeutics Corp股票,Silexion Therapeutics Corp股票老虎,Silexion Therapeutics Corp股票老虎国际,Silexion Therapeutics Corp行情,Silexion Therapeutics Corp股票行情,Silexion Therapeutics Corp股价,Silexion Therapeutics Corp股市,Silexion Therapeutics Corp股票价格,Silexion Therapeutics Corp股票交易,Silexion Therapeutics Corp股票购买,Silexion Therapeutics Corp股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Silexion Therapeutics Corp(SLXN)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供Silexion Therapeutics Corp(SLXN)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}